137 related articles for article (PubMed ID: 36867463)
1. Borderline With Bad Behavior: An Unusual Low-grade Serous Carcinoma With Dedifferentiation From a Serous Borderline Tumor.
Strickland AL; Maniar KP; Tanner E; Shanes E; Jennings L; Wei JJ
Int J Gynecol Pathol; 2023 May; 42(3):241-246. PubMed ID: 36867463
[TBL] [Abstract][Full Text] [Related]
2. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
3. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
Boyd C; McCluggage WG
Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
5. Grade 1 peritoneal serous carcinomas: a report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors.
Weir MM; Bell DA; Young RH
Am J Surg Pathol; 1998 Jul; 22(7):849-62. PubMed ID: 9669347
[TBL] [Abstract][Full Text] [Related]
6. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
Kurman RJ
Ann Oncol; 2013 Dec; 24 Suppl 10():x16-21. PubMed ID: 24265397
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
9. Low-grade serous tumors of ovary.
Bell DA
Int J Gynecol Pathol; 2014 Jul; 33(4):348-56. PubMed ID: 24901394
[TBL] [Abstract][Full Text] [Related]
10. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
Vang R; Shih IeM; Kurman RJ
Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
[TBL] [Abstract][Full Text] [Related]
11. Precursors and pathogenesis of ovarian carcinoma.
Lim D; Oliva E
Pathology; 2013 Apr; 45(3):229-42. PubMed ID: 23478230
[TBL] [Abstract][Full Text] [Related]
12. Assessing the landscape of ovarian serous borderline tumors.
Messini I; Doulgeraki T; Chrysanthakis D; Yiannou P; Gavresea T; Papadimitriou C; Panoskaltsis T; Voulgaris Z; Vlachos A; Pavlakis K
Int J Gynecol Cancer; 2019 Mar; 29(3):572-578. PubMed ID: 30659030
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
[TBL] [Abstract][Full Text] [Related]
14. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
15. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
16. Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.
Bijsmans IT; Smits KM; de Graeff P; Wisman GB; van der Zee AG; Slangen BF; de Bruïne AP; van Engeland M; Sieben NL; Van de Vijver KK
Mod Pathol; 2011 Mar; 24(3):463-70. PubMed ID: 21102419
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
18. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
19. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
20. Cytologic identification of serous neoplasms in peritoneal fluids.
Weir MM; Bell DA
Cancer; 2001 Oct; 93(5):309-18. PubMed ID: 11668465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
